eHealth, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by eHealth, Inc. on February 28, 2022. The filing discloses the appointment of a new senior executive and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $400,000 annually.
- Target Bonus: 75% of annual base salary (prorated for 2022).
- Sign-on Bonus: $100,000 (subject to repayment if employment ends within one year).
- Equity Awards: Approximately $1,000,000 in time-based Restricted Stock Units (RSUs) vesting over four years, and approximately $1,000,000 in performance-based RSUs tied to stock price targets.
Material Changes
On February 28, 2022, the Company appointed Roman Rariy as Chief Operating Officer and Chief Transformation Officer, effective March 1, 2022. Mr. Rariy joins from Lionbridge, where he served as Chief Transformation Officer. This appointment represents a material change in the Company's executive leadership structure.
Outlook, Risks, and Contingencies
Management Commentary: The appointment is intended to drive enterprise-wide initiatives focused on organization and technology operations, leveraging Mr. Rariy's prior experience at Lionbridge and Kraft Heinz.
Severance Contingencies: A Severance Agreement was executed providing for 12 months of base salary and benefits if terminated "without cause" or resigning for "good reason." In the event of a change of control within 12 months, severance includes 100% of the target bonus and full vesting of time-based equity.
Risks: The sign-on bonus is contingent on Mr. Rariy remaining employed for one year; otherwise, the advanced amount must be repaid.
Investor Verification Checklist
- Verify the exact vesting schedule and performance metrics for the $1,000,000 performance-based RSU grant.
- Review the full text of the Severance Agreement and Sign-On Bonus Repayment Agreement when filed as exhibits to the Form 10-Q for the quarter ended March 31, 2022.
- Confirm the impact of the new executive leadership on the Company's strategic transformation initiatives.